Cancer patients can respond very differently to the same treatment, while current testing may not reliably identify the therapy most likely to work for each tumor.
R&D Focus
Strike Pharma is using the company’s proprietary Adaptable Drug Affinity Conjugate (ADAC)
Innovative Solution
The company employs an antibody-based technique based on the genetic profile of each patient’s tumor that destroys tumor cells while leaving other normal cells alone in the body. The company offers patients a low-cost, effective medication while minimizing the danger of unwanted effects.
Investment Funding
Last Funding Stage
Venture - Series Unknown
Total Funding Amount
6.M
Last Funding Amount
4.82M
Last Funding Date
22-02-2022
Lead Investors
Almi Invest, EIR Ventures, Flerie Invest
About
Strike Pharma is using the company’s proprietary Adaptable Drug Affinity Conjugate (ADAC). The company employs an antibody-based technique based on the genetic profile of each patient’s tumor that destroys tumor cells while leaving other normal cells alone in the body. The company offers patients a low-cost, effective medication while minimizing the danger of unwanted effects.
Something missing or incorrect on this page? Help us enrich this information
